Top

The Egyptian Journal of Neurology, Psychiatry and Neurosurgery

Published in:

Open Access 01-12-2021 | Mood Disorders | Research

Cognitive impairment and depression in patients with relapsing–remitting multiple sclerosis depending on age and neuroimaging findings

Authors: Oksana O. Kopchak, Tetiana A. Odintsova

Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery | Issue 1/2021

Abstract

Background

Multiple sclerosis is an insidious, disabling, both physically and mentally, demyelinating disease of the central nervous system. This work aims to evaluate relationships between cognitive impairment in separate domains, depression and their correspondence with MRI-findings, as well as the influence on each other’s manifestations, in patients with relapsing–remitting multiple sclerosis.

Results

Visual–spatial/executive functions and memory domains suffered more frequently than others in the study subjects under 40 years; in patients over 40 years old memory, visual–spatial/executive functions and abstract thinking impairment prevailed the most. Such cognitive domains as memory, language, abstract thinking, visual–spatial and executive functions were impacted in both groups of patients even without the apparent cognitive decline according to MoCA scale. Presence of depression impacted language and attention more prominently than the rest of the domains only in participants younger 40 years. According to the MRI, frontal lobe, corpus callosum and periventricular area were affected more often compared to other brain regions in case of cognitive impairment; meanwhile, combined lesions of frontal lobe and corpus callosum, fronto-temporal region were associated with depression.

Conclusion

Cognitive impairment and depression are one of the common, yet disabling and socially disrupting manifestations of MS. Quite frequently such complaints are neglected or considered as parts of comorbidities. At the same time cognitive impairment can be amplified by depression, especially in patients under 40 years.

Walton V, King R, Rechtman L, Kaye W, Leray E, Marrie RA, Robertson N, La Rocca N, Uitdehaag B, van der Mei I, Wallin M, Helme A, Napier CA, Rijke N, Baneke P. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Multiple Sclerosis J. 2020;14:1816–21. https://doi.org/10.1177/1352458520970841.CrossRef

Kobelt G, Thompson A, Berg J, Gannedahl M, Eriksson J, MSCOI Study Group. European Multiple Sclerosis Platform New insights into the burden and costs of multiple sclerosis in Europe. Mult Scler. 2017;23(8):1123–36. https://doi.org/10.1177/1352458517694432.CrossRefPubMedPubMedCentral

Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintoré M, Traboulsee L, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. The Lancet Neurology. 2018;17:162–73. https://doi.org/10.1016/S1474-4422(17)30470-2.CrossRefPubMed

Andravizou A, Dardiotis E, Artemiadis A, Sokratous AM, Siokas V, Tsouris Z, Aloizou AM, Nikolaidis I, Bakirtzis C, Tsivgoulis G, Deretzi G, Grigoriadis N, Bogdanos DP, Hadjigeorgiou GM. Brain atrophy in multiple sclerosis: mechanisms, clinical relevance and treatment options. Autoimmunity Highlights. 2019;10:7. https://doi.org/10.1186/s13317-019-0117-5.CrossRefPubMedPubMedCentral

Giovannoni G, Butzkueven H, Dhib-Jalbut S, Hobart J, Kobelt G, Pepper G, Sormani MP, Thalheim C, Traboulsee A, Vollmer T. Brain health: time matters in multiple sclerosis. Multiple Sclerosis Related Disord. 2016;9:S5-48. https://doi.org/10.1016/j.msard.2016.07.003.CrossRef

Tsivgoulis G, Katsanos AH, Grigoriadis N, Hadjigeorgiou GM, Heliopoulos I, Papathanasopoulos P, Dardiotis E, Kilidireas C, Voumvourakis K. The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis. Ther Adv Neurol Disord. 2015;8(5):193–202. https://doi.org/10.1177/1756285615600381.CrossRefPubMedPubMedCentral

Koubiyr I, Deloire M, Coupé P, Dulau C, Besson P, Moroso A, Planche V, Tourdias T, Brochet B, Ruet A. Differential gray matter vulnerability in the 1 year following a clinically isolated syndrome. Front Neurol. 2018;9:824. https://doi.org/10.3389/fneur.2018.00824.CrossRefPubMedPubMedCentral

Turner AP, Hartoonian N, Hughes AJ, Arewasikporn A, Alschuler KN, Sloan AP, Ehde DM, Haselkorn JK. Physical activity and depression in MS: The mediating role of behavioral activation. Disability Health J. 2019;12(4):635–40. https://doi.org/10.1016/j.dhjo.2019.04.004.CrossRef

van Geest Q, Boeschoten RE, Keijzer MJ, Steenwijk MD, Pouwels PJ, Twisk JW, Smit JH, Uitdehaag BM, Geurts JJ, van Oppen P, Hulst HE. Fronto-limbic disconnection in patients with multiple sclerosis and depression. Multiple Sclerosis (Houndmills, Basingstoke, England). 2019;25(5):715–26. https://doi.org/10.1177/1352458518767051.CrossRef

10.

Oset M, Stasiolek M, Matysiak M. Cognitive dysfunction in the early stages of multiple sclerosis—how much and how important? Curr Neurol Neurosci. 2020. https://doi.org/10.1007/s11910-020-01045-3.CrossRef

11.

Kurtzke JF. Rating neurological impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;3:1444–52. https://doi.org/10.1212/WNL.33.11.1444.CrossRef

12.

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatric Soc. 2005;53:695–9. https://doi.org/10.1111/j.1532-5415.2005.53221.x.CrossRef

13.

Beck A, Ward ST, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4:561–71. https://doi.org/10.1001/archpsyc.1961.01710120031004.CrossRefPubMed

14.

Oset M, Stasiolek M, Matysiak M. Cognitive dysfunction in the early stages of multiple sclerosis—how much and how important? Curr Neurol Neurosci. 2020;20:22. https://doi.org/10.1007/s11910-020-01045-3.CrossRef

15.

Moccia M, Lanzillo R, Palladino R, Chang KC, Costabile T, Russo C, et al. Cognitive impairment at diagnosis predicts 10-year multiple sclerosis progression. Mult Scler. 2016;22(5):659–67. https://doi.org/10.1177/1352458515599075.CrossRefPubMed

16.

Migliore S, Ghazaryan A, Simonelli I, Pasqualetti P, Squitieri F, Curcio G, Landi D, Palmieri MG, Moffa F, Filippi MM, Vernieri F. Cognitive impairment in relapsing-remitting multiple sclerosis patients with very mild clinical disability. Behav Neurol. 2017;04:1–10. https://doi.org/10.1155/2017/7404289.CrossRef

17.

Du XF, Liu J, Hua QF, Wu YJ. Relapsing-remitting multiple sclerosis is associated with regional brain activity deficits in motor—and cognitive-related brain areas. Front Neurol. 2019;2019(10):1136. https://doi.org/10.3389/fneur.2019.01136.CrossRef

18.

Trenova AG, Slavov GS, Manova MG, Aksentieva JB, Miteva LD, Stanilova SA. Cognitive impairment in multiple sclerosis. Folia Med. 2016;58(3):157–63. https://doi.org/10.1515/folmed-2016-0029.CrossRef

19.

Brochet B, Ruet A. Cognitive impairment in multiple sclerosis with regards to disease duration and clinical phenotypes. Front Neurol. 2019. https://doi.org/10.3389/fneur.2019.00261.CrossRefPubMedPubMedCentral

20.

Schneider R, Genç E, Ahlborn C, Gold R, Lukas C, Bellenberg B. Temporal dynamics of diffusion metrics in early multiple sclerosis and clinically isolated syndrome: a 2-year follow-up tract-based spatial statistics study. Front Neurol. 2019. https://doi.org/10.3389/fneur.2019.01165.CrossRefPubMedPubMedCentral

21.

Whitehouse CE, Fisk JD, Bernstein CN, Berrigan LI, Bolton JM, Graff LA, Hitchon CA, Marriott JJ, Peschken CA, Sareen J, Walker JR, Stewart SH, Marrie RA, for the CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Comorbid anxiety, depression, and cognition in MS and other immune-mediated disorders. Neurology. 2019;92(5):e406–17. https://doi.org/10.1212/WNL.0000000000006854.CrossRefPubMedCentral

22.

Boeschoten RE, Braamse AMJ, Beekman ATF, Cuijpers P, van Oppen P, Dekker J, et al. Prevalence of depression and anxiety in multiple sclerosis: a systematic review and meta-analysis. J Neurol Sci. 2017;372:331–41. https://doi.org/10.1016/j.jns.2016.11.067.CrossRefPubMed

23.

Golan D, Doniger GM, Wissemann K, Zarif M, Bumstead B, Buhse M, et al. The impact of subjective cognitive fatigue and depression on cognitive function in patients with multiple sclerosis. Mult Scler. 2018;24(2):196–204. https://doi.org/10.1177/1352458517695470.CrossRefPubMed

24.

Elshebawy H, Fahmy EM, Elfayoumy NM, Abdelalim AM, Ismail RI. Clinical predictors to cognitive impairment in multiple sclerosis patients. Egypt J Neurol Psychiatry Neurosurg. 2021;57:38. https://doi.org/10.1186/s41983-021-00292-6.CrossRef

Title: Cognitive impairment and depression in patients with relapsing–remitting multiple sclerosis depending on age and neuroimaging findings
Authors: Oksana O. Kopchak
Tetiana A. Odintsova
Publication date: 01-12-2021
Publisher: Springer Berlin Heidelberg
Keywords: Mood Disorders
Affective Disorder
Multiple Sclerosis
Magnetic Resonance Imaging
Magnetic Resonance Imaging
Published in: The Egyptian Journal of Neurology, Psychiatry and Neurosurgery / Issue 1/2021
Electronic ISSN: 1687-8329
DOI: https://doi.org/10.1186/s41983-021-00376-3

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cognitive impairment and depression in patients with relapsing–remitting multiple sclerosis depending on age and neuroimaging findings

Abstract

Background

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

Migraine in patients with rheumatoid arthritis and its relation to disease activity

Obsessive–compulsive disorder post-COVID-19: a case presentation

Multidisciplinary management of juvenile nasopharyngeal angiofibroma

Case reports of cerebral sinus venous thrombosis in COVID-19 patients

Depression among health workers caring for patients with COVID-19 in Egypt

A study of anxiety, depression and stress symptoms among Fayoum medical students during COVID-19 lockdown, Egypt